Dr. John Cush RheumNow
1 week ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment
sheila RHEUMarampa
1 week ago
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
Bella Mehta bella_mehta
1 week ago
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow
Summary below. https://t.co/QC0Li38eh6
Aurelie Najm AurelieRheumo
1 week ago
SCOOT study oral split-dose vs SC MTX RA
Primary outcome EULAR mod/good response wk16
Non-inferiority NOT met
EULAR good response lower with oral split-dose OR 0.53
ACR50 lower with oral split-dose OR 0.51
Safety oral split-dose Higher transaminitis (>2× ULN)
3 serious AEs https://t.co/c8etFKtGwo
Jiha Lee JihaRheum
1 week ago
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206
Mrinalini Dey DrMiniDey
1 week ago
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow
Mrinalini Dey DrMiniDey
1 week ago
#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week ago
#EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow
https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39
Nelly ZIADE 🍀 Nellziade
1 week ago
🔬 Does synovial biopsy-guided treatment outperform standard care in PsA?
YES - 68% vs 45% DAPSA remission/LDA in 45pts
OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm
Antoni Chan MD (Prof) synovialjoints
1 week ago
Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints
1 week ago
Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow
Nelly ZIADE 🍀 Nellziade
1 week ago
🤰What happens to RA disease activity during pregnancy?
🔴 Most remain stable
🔴 70% with high disease activity at baseline improve
🔴 20% flare again post-partum
✨ACPA+ improve more
✨ Better outcomes after 2016 (after modern treatments)
OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6
Dr. John Cush RheumNow
1 week ago
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
